Company: HRTX
Filing Date: 2025-09-09
Form Type: S-3
Source: 0000950170-25-113830
Chunk: 31

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: S-3
Chunk 31
---
463 |     | *          |
| Adage Capital Partners, L.P.(2)(6)                          |     |   3,333,325 |     |   3,333,325 |     |          — |     | —          |
| Entities Affiliated with JW Partners, LP(2)(7)              |     |   1,333,330 |     |   1,333,330 |     |          — |     | —          |

___________________

| *   | Indicates beneficial ownership of less than 1% of the total issued and outstanding shares of Common Stock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| (1) | Represents the number of shares of Common Stock that will be beneficially owned by the applicable Selling Stockholder after completion of this offering based on the assumption that (i) the Company has received Stockholder Approval and all of the shares of Series A Convertible Preferred Stock have automatically converted into 5,241,410 shares of Common Stock, (ii) the Company has received Stockholder Approval and all outstanding Notes have been converted to 19,444,444 shares of Common Stock pursuant to the Note Purchase Agreement, (iii) all of the shares of Common Stock registered for resale by the registration statement of which this prospectus is a part will be sold and (iv) no other shares of Common Stock will be acquired or sold by the Selling Stockholder before completion of this offering. However, the Selling Stockholder may sell all, part or none of their shares of Common Stock offered pursuant to this prospectus and may sell all, part or none of their Common Stock pursuant to one or more exemptions from the registration provisions of the Securities Act. Applicable percentage ownership after the offering is based on 208,000,521 shares of Common Stock outstanding as of September 3, 2025, after giving effect to 5,241,410 shares of Common Stock issuable upon conversion of all outstanding Series A Convertible Preferred Stock issued pursuant to the Purchase Agreement and 19,444,444 shares of Common Stock issuable upon conversion of all outstanding Notes issued pursuant to the Note Purchase Agreement. |

<div align='center'>17</div>

| (2) | Represents the number of shares of Common Stock that will be beneficially owned by the applicable Selling Stockholder after completion of this offering based on the assumption that (i) the Company has received Stockholder Approval and all of the shares of Series A Convertible Preferred Stock have automatically converted into